CA2335366A1 - Compositions et methodes de traitement d'une cholesterolemie elevee - Google Patents
Compositions et methodes de traitement d'une cholesterolemie elevee Download PDFInfo
- Publication number
- CA2335366A1 CA2335366A1 CA002335366A CA2335366A CA2335366A1 CA 2335366 A1 CA2335366 A1 CA 2335366A1 CA 002335366 A CA002335366 A CA 002335366A CA 2335366 A CA2335366 A CA 2335366A CA 2335366 A1 CA2335366 A1 CA 2335366A1
- Authority
- CA
- Canada
- Prior art keywords
- geranylgeranyl
- geranylgeraniol
- hmg
- coa reductase
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des compositions et des méthodes de traitement d'une cholestérolémie élevée chez un mammifère tout en évitant l'apparition d'effets secondaires indésirables tels que la myopathie. Ces compositions contiennent une combinaison d'une dose pharmaceutiquement efficace d'un inhibiteur de la 3-hydroxy-3-méthyl-glutaryle coenzyme A (HMG-CoA) réductase et d'un composé de géranylgéraniol. Ces compositions sont destinées à être administrées à un mammifère nécessitant un tel traitement.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9052798P | 1998-06-24 | 1998-06-24 | |
US60/090,527 | 1998-06-24 | ||
GBGB9817167.1A GB9817167D0 (en) | 1998-08-06 | 1998-08-06 | Compositions and methods for treating elevated blood cholesterol |
GB9817167.1 | 1998-08-06 | ||
PCT/US1999/013887 WO1999066929A1 (fr) | 1998-06-24 | 1999-06-21 | Compositions et methodes de traitement d'une cholesterolemie elevee |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2335366A1 true CA2335366A1 (fr) | 1999-12-29 |
Family
ID=26314174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002335366A Abandoned CA2335366A1 (fr) | 1998-06-24 | 1999-06-21 | Compositions et methodes de traitement d'une cholesterolemie elevee |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1089731A4 (fr) |
JP (1) | JP2002518448A (fr) |
AU (1) | AU754767B2 (fr) |
CA (1) | CA2335366A1 (fr) |
WO (1) | WO1999066929A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2209890T3 (es) | 1999-05-24 | 2004-07-01 | American River Nutrition, Inc. | Tocotrienoles y geranilgeraniol de subproductos de bixa orellana. |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
EP2465516A1 (fr) | 2003-04-08 | 2012-06-20 | Barrie Tan | Compositions d'extrait de rocou, y compris les géraniols géranyl et procédés d'utilisation |
WO2010098906A1 (fr) * | 2009-02-24 | 2010-09-02 | Madeira Therapeutics | Formulations de statine liquide |
US20120171286A1 (en) * | 2009-04-27 | 2012-07-05 | Beth Isreal Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of statin-induced myopathy |
US9045403B2 (en) | 2012-02-29 | 2015-06-02 | Coyote Pharmaceuticals, Inc. | Geranyl geranyl acetone (GGA) derivatives and compositions thereof |
TW201427938A (zh) * | 2012-10-01 | 2014-07-16 | Coyote Pharmaceuticals Inc | 香葉基香葉基丙酮(gga)和其衍生物之製備方法及彼等與脲或硫脲之共結晶作用 |
US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8105781A1 (es) * | 1979-07-27 | 1981-06-16 | Sankyo Co | Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos. |
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
JPH04502167A (ja) * | 1989-10-13 | 1992-04-16 | メダフオール | 長鎖脂肪アルコール誘導体、特に細胞栄養分子及び細胞保護分子としてのその使用、並びに、該誘導体を含有する医薬組成物 |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5639653A (en) * | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
IL112639A0 (en) * | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
US5574025A (en) * | 1994-10-26 | 1996-11-12 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
IT1276162B1 (it) * | 1995-11-23 | 1997-10-27 | Baldacci Lab Spa | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche |
JPH1087480A (ja) * | 1996-09-13 | 1998-04-07 | Eisai Co Ltd | 抗動脈硬化治療剤 |
US5763646A (en) * | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
-
1999
- 1999-06-21 JP JP2000555615A patent/JP2002518448A/ja not_active Withdrawn
- 1999-06-21 AU AU46989/99A patent/AU754767B2/en not_active Ceased
- 1999-06-21 WO PCT/US1999/013887 patent/WO1999066929A1/fr not_active Application Discontinuation
- 1999-06-21 EP EP99930451A patent/EP1089731A4/fr not_active Withdrawn
- 1999-06-21 CA CA002335366A patent/CA2335366A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1089731A1 (fr) | 2001-04-11 |
AU4698999A (en) | 2000-01-10 |
AU754767B2 (en) | 2002-11-21 |
WO1999066929A1 (fr) | 1999-12-29 |
EP1089731A4 (fr) | 2003-06-18 |
JP2002518448A (ja) | 2002-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2632967T3 (es) | Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma | |
EP1919466B9 (fr) | Formulations pour le traitement des anormalites liees aux lipoproteines comprenant une statine et un derive de la methylnicotinamide | |
EP1660066B1 (fr) | Composition pharmaceutique comprenant une combinaison de metformine et une statine | |
US11786482B2 (en) | Compositions and methods using a cannabinoid to enhance bioavailability of a statin | |
US20070166321A1 (en) | Compositions and Methods for Reducing Cholesterol and Inflammation | |
AU754767B2 (en) | Compositions and methods for treating elevated blood cholesterol | |
US9642860B2 (en) | Combinations of corroles and statins | |
EP0373507A1 (fr) | Combinaison d'un inhibiteur de HMG-CoA réductase et autres agents réduisant le cholestérol du sérum et méthode pour diminuer le cholestérol du sérum utilisant celle combinaison | |
KR101258422B1 (ko) | 신규의 트리글리세리드 저하제 | |
JPH06500537A (ja) | アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用 | |
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
CA2336192A1 (fr) | Compositions et methodes de traitement d'une cholesterolemie elevee | |
US20040023919A1 (en) | Blood lipid ameliorant composition | |
KR101086040B1 (ko) | 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체 | |
US5461072A (en) | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | |
Jurkowski | Statins regulate IL-1β-induced RANKL and OPG production by human gingival fibroblasts | |
CA2494801A1 (fr) | Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase | |
WO2002098353A2 (fr) | Compositions et methodes d'inhibition de la resorption osseuse | |
RU2008144912A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов | |
JP2007063224A (ja) | チロシナーゼ活性阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |